MedPath

A Prospective, Single-center, Randomized, Controlled, Open-label, Pilot Study to Compare the Effectiveness and Safety of DIuretics Add-On Strategy in Acute Decompensated Heart Failure Patients (DIOS II)

Not Applicable
Withdrawn
Conditions
Congestive Heart Failure
Interventions
Drug: furosemid/spironolactone
Drug: metolazone/spironolactone
Registration Number
NCT02047422
Lead Sponsor
Yonsei University
Brief Summary

To compare the effectiveness and safety of diuretics add-on strategy in chronic heart failure patients

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  1. dyspnea at rest or minimal activity
  2. tachypnea (respiratory rate > 20/min) or rales or pulmonary edema on chest X-ray
Exclusion Criteria
  1. hospitalization for acute heart failure decompensation
  2. cardiogenic shock (Systolic Blood Pressure < 80mmHg)
  3. Need or plan for renal replacement therapy (dialysis, kidney transplant)
  4. serum creatine level > 2.5mg/dl
  5. serum potassium (K+) > 5.5mg/dl
  6. Age > 80 years old or poor compliance patients
  7. allergy, adverse drug reaction, hypersensitivity to any kinds of diuretics
  8. life expectancy < 6 months (e.g. metastatic malignancy, liver cirrhosis)
  9. pregnancy or women at age of childbearing potential

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Add furosemid/spironolactonefurosemid/spironolactone-
Add metolazone/spironolactonemetolazone/spironolactone-
Add metolazone/no spironolactonemetolazone-
Add furosemide/no spironolactoneFurosemide-
Primary Outcome Measures
NameTimeMethod
urine output changefrom admission to Hospital Day (HOD)#4

efficacy of diuretics add-on therapy, urine output change

Secondary Outcome Measures
NameTimeMethod
serum creatinine changefrom admission to HOD#4

safety of diuretics add-on therapy, serum creatinine change

© Copyright 2025. All Rights Reserved by MedPath